-
Clin Cancer Res: PD1 blocking enhances the effectiveness of IAM1-targeted CAR T cells in the treatment of advanced thyroid cancer.
Time of Update: 2020-09-23
addition, the tumor targeting effect and T-cell dynamics of ICM1 targeted CAR T cells and anti-PD1 antibody mono-use and joint therapy were studied in the ATC heterogeneous graft model.
-
Clin Cancer Res: The early antivascular and tumor-resistant effects of icing on concentration dependence in NSCLC.
Time of Update: 2020-09-23
the trial recruited patients with non-small cell lung cancer who were to undergo surgery for 10-14 days of equconazole (300 mg, oral, 2/day).
icconazole showed early antivascular, metabolic and tumor-resistant effects of concentration dependence in patients with non-small cell lung cancer.
-
Genome Med: Wu Dasun Chengchao and others reveal the important role of LINC00301 in the progress of non-small cell lung cancer and tumor immunity.
Time of Update: 2020-09-23
This study reveals the carcinogenic effect of LINC00301 in NSCLC clinical specimens, cells and animal levels, elaborates the specific role and molecular regulatory mechanism of LINC00301 in NSCLC tumor occurrence, development, metastasis and immunosuppression microencular formation, and provides a new understanding for NSCLC tumor occurrence and immunotherapy.
-
JAMA Oncol: Triple negative breast cancer treatment added "platinum program", five-year disease-free survival rate of 86.5%
Time of Update: 2020-09-23
Recently, a study published by Professor Zhai Zhimin of Breast Surgery and Professor Yu Koda of Fudan University's Affiliated Oncology Hospital confirmed that the "platinum solution" for three-negative breast cancer treatment - the week-long intensive application of the chemotherapy drug yew alcohol combination carpentin ("platinum" commonly known as "platinum", "carpentry" is platinum-containing chemotherapy drugs), can improve the five-year survival rate of such patients to 86.5 percent, far higher than the standard complementary chemotherapy program.
-
Nature: Cancer cells evade the immune system by fighting for methionine, Professor Zhai Weiping proposed the strategy of "depriving methionine and starving cancer cells".
Time of Update: 2020-09-23
study illustrates the link between these three questions, suggesting that targeting tumor cell methionine transport proteins can promote immune responses in different tumors.
-
CELL: Single-cell sequencing reveals how drug therapy induced the evolution of lung cancer in humans.
Time of Update: 2020-09-23
single-cell map of more than 20,000 cancer and tumor micro-environments (TME) exposes a rich and dynamic tumor ecosystem, and scRNA-seq of cancer cells reveals clinically d'ethonically available targeted cancer genes.
-
Professor Wu Jie: What is the relationship between MHT and female malignancies? These questions must be understood!
Time of Update: 2020-09-23
To this end, China Obstetrics and Gynaecology Online invited Professor Wu Jie of Nanjing Medical University First Affiliated Hospital/Jiangsu Provincial People's Hospital on the relationship between MHT and female malignant tumors, the current application of MHT at home and abroad, the risk and benefit evaluation of MHT, the application points of MHT in female malignant tumor survivors, different MHT drugs and different start-up times.
-
Hutchison Whampoa launched phase II trials of HMPL-453 for the treatment of advanced liver bile duodenal cancer.
Time of Update: 2020-09-23
, Hutchison Whampoa has begun a Phase II clinical study of HMPL-453 for the treatment of IHCC.
the clinical study is a one-arm, multi-center, open-label Phase II study designed to assess the efficacy, safety, and pharmacodynamics of HMPL-453 in patients with advanced FGFR2 fusion IHCC who failed in at least one systematic treatment.
-
J Clin Oncol: Post-study exploration analysis of the ARIEL3 trial.
Time of Update: 2020-09-23
the average Q-TWiST difference between the Rukapali group and the placebo group in the ITT population, BRCA mutation queue, HRD queue and BRCA wild type/LOH low patient group was 6.88 months, 9.73 months, 8.11 months and 3.35 months, respectively, using TOX defined by level 3 TEAE.
-
Oncology patients more convenient, Peking University Cancer Hospital opened an online video clinic.
Time of Update: 2020-09-18
"The development of Internet consultation services reduces patient visits and non-medical expenses, reducing the risk of cross-infection in hospitals." Lin Ningjing, chief physician of the lymphoma department at Peking University Cancer Hospital, said.
-
Beijing 90% of the medical examination center to carry out gastrointestinal tumor "three early" collaborative screening.
Time of Update: 2020-09-18
Zhang Kai, deputy director of the cancer prevention department of the Oncology Hospital of the Chinese Academy of Medical Sciences, said that the initial screening technology program promoted by the "Three Mornings" collaborative screening program has good screening effectiveness, enabling the medical examination center to detect as many high-risk groups of gastrointestinal tumors as possible by means of non-invasive compliance.
-
On September 7, the "Special Needs Clinic" of Shenzhen Hospital of the Oncology Hospital of the Chinese Academy of Medical Sciences opened.
Time of Update: 2020-09-18
He Jie, president of the Oncology Hospital of the Chinese Academy of Medical Sciences and secretary of the Shenzhen Hospital Party Committee, will lead a team of experts from the "strongest line-up" of the National Cancer Center to fly to Shenzhen to assist in the opening of special needs clinics.
-
World Lymphoma Day 2020: Co-talk lymphoma management, to help patients towards cure.
Time of Update: 2020-09-18
On September 15, 2020, on the occasion of World Lymphoma Day, the Health Care Channel of the National Health Commission, the Rehabilitation Society of the Chinese Anti-Cancer Association, the Beijing
-
The training course for the construction of thousands of deans in the grass-roots cancer center was successfully concluded.
Time of Update: 2020-09-18
"'Basic Oncology Center Construction Training Program' can help Chongqing county-level medical institutions to establish cancer centers, improve the diagnosis and treatment capacity of medical institutions in various regions and at all levels, so that cancer patients get all-round, full-cycle, high-quality, standardized treatment." Huang Ming, party secretary and director of the Chongqing Municipal Health And Wellness Commission, said.
-
Rindopepimut combined with Beval monoantiviral therapy relapse GBM.
Time of Update: 2020-09-13
researchers randomly divided 73 relapsed GBM patients who received EGFRvIII-positive treatment between May 2012 and May 2014 into two groups: 36 cases of Redopepimut and Beval monoantigen therapy; study endpoint indicator is a six-month progress-free lifetime (PFS-6).
-
The therapeutic effect of Ivosidenib on IDH mutant glioma.
Time of Update: 2020-09-12
results, the researchers quantified tumor volume in 24 patients without fortified glioma before and during ivosidenib treatment.
4 patients without reinforced glioma, MRI imaging and tumor volume growth curve before and after ivosidenib treatment.
-
Phase III clinical study of Odivo (Navulimab) adjuvant treatment of esophageal cancer and gastroesophageal junction cancer after surgery, CheckMate-577 reached the primary endpoint of disease-free survival
Time of Update: 2020-09-12
The key Phase III clinical studies of the first-line therapeutic effect of metastatic gastric cancer, gastroesophageal connecting cancer or esophageal adenocarcinoma patients reached the total end-of-life (OS) and non-progressive survival (PFS) of the main study; OS benefits were also observed in all random populations.
-
Comparison of methionine with fluorine thymus PET-CT diagnosis of IDH mutant glioma.
Time of Update: 2020-09-12
the average T/N ratio of IDH1 wild glioma FLT-PET/CT was significantly higher than that of IDH1 mutant glioma (P-0.005), but the met-PET/CT test results were not so.
-
The treatment of beva monoantigen anti-combined tymoazine is expected to improve the survival of GBM patients.
Time of Update: 2020-09-12
Nobuhiro Hata of Neurosurgery, Kyushe University School of Medical Sciences, Japan, and others analyzed the effects of tymoazine-combined beva monoantigen on the overall survival rate of GBM patients using clinical data from the treatment of GBM in Japan, published in the February 2020 issue of Journal of Neuro-Oncology.
-
Line treatment of gastric cancer/esophageal cancer BMS immunocombination therapy reaches phase 3 clinical endpoint
Time of Update: 2020-09-11
addition, the CheckMate-649 study evaluated the effectiveness of Odivo's combined epipentherapy chemotherapy for patients with stomach cancer, gastroesophageal connecting cancer, or esophageal adenocarcinoma.
